{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:12:21Z","timestamp":1790835141784,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1007\/s00213-009-1718-x","type":"journal-article","created":{"date-parts":[[2009,11,24]],"date-time":"2009-11-24T11:52:50Z","timestamp":1259063570000},"page":"179-189","source":"Crossref","is-referenced-by-count":73,"title":["LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor"],"prefix":"10.1007","volume":"208","author":[{"given":"Adam L.","family":"Halberstadt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,11,25]]},"reference":[{"key":"1718_CR1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0091-3057(85)90022-X","volume":"23","author":"LM Adams","year":"1985","unstructured":"Adams LM, Geyer MA (1985) Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide. Pharmacol Biochem Behav 23:461\u2013468","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR2","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1046\/j.1460-9568.1999.00726.x","volume":"11","author":"VL Arvanov","year":"1999","unstructured":"Arvanov VL, Liang X, Russo A, Wang R (1999) LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex. Eur J NeuroSci 11:3064\u20133072","journal-title":"Eur J NeuroSci"},{"key":"1718_CR3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00702-005-0386-1","volume":"113","author":"H Bene\u0161","year":"2006","unstructured":"Bene\u0161 H, Deissler A, Rodenbeck A, Engfer A, Kohnen R (2006) Lisuride treatment of Restless Legs Syndrome: first studies with monotherapy in de novo patients and in combination with levodopa in advanced disease. J Neural Transm 113:87\u201392","journal-title":"J Neural Transm"},{"key":"1718_CR4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0022-3565(25)20333-0","volume":"258","author":"KD Burris","year":"1991","unstructured":"Burris KD, Breeding M, Sanders-Bush E (1991) (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5-HT1C receptor agonist. J Pharmacol Exp Ther 258:891\u2013896","journal-title":"J Pharmacol Exp Ther"},{"key":"1718_CR5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","volume":"594","author":"D Cussac","year":"2008","unstructured":"Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I (2008) Agonist-directed trafficking of signaling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 594:32\u201338","journal-title":"Eur J Pharmacol"},{"key":"1718_CR6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0091-3057(94)90542-8","volume":"48","author":"NA Darmani","year":"1994","unstructured":"Darmani NA, Mock OB, Towns LC, Gerdes CF (1994) The head twitch response in the least shrew (Cryptotis parva) is a 5-HT2- and not a 5-HT1C-mediated phenomenon. Pharmacol Biochem Behav 48:383\u2013396","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s002130050585","volume":"136","author":"CT Egan","year":"1998","unstructured":"Egan CT, Herrick-Davis K, Miller K, Glennon RA, Teitler M (1998) Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology 136:409\u2013414","journal-title":"Psychopharmacology"},{"key":"1718_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K","volume":"35","author":"C Egan","year":"2000","unstructured":"Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K (2000) Agonist high and low state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT2A and 5-HT2C receptors. Synapse 35:144\u2013150","journal-title":"Synapse"},{"key":"1718_CR9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF02246074","volume":"121","author":"D Fiorella","year":"1995","unstructured":"Fiorella D, Rabin RA, Winter JC (1995a) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology 121:347\u2013356","journal-title":"Psychopharmacology"},{"key":"1718_CR10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02246075","volume":"121","author":"D Fiorella","year":"1995","unstructured":"Fiorella D, Rabin RA, Winter JC (1995b) Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: reassessment of LSD false positives. Psychopharmacology 121:357\u2013363","journal-title":"Psychopharmacology"},{"key":"1718_CR11","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1046\/j.1471-4159.1999.0722127.x","volume":"72","author":"LW Fitzgerald","year":"1999","unstructured":"Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR (1999) High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem 72:2127\u20132134","journal-title":"J Neurochem"},{"key":"1718_CR12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.neuropharm.2007.03.013","volume":"52","author":"EE Garcia","year":"2007","unstructured":"Garcia EE, Smith RL, Sanders-Bush E (2007) Role of Gq protein in behavioral effects of the hallucinogenic drug 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane. Neuropharmacology 52:1671\u20131677","journal-title":"Neuropharmacology"},{"key":"1718_CR13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0304-3940(85)90245-9","volume":"60","author":"R Gerber","year":"1985","unstructured":"Gerber R, Barbaz BJ, Martin LL, Neale R, Williams M, Liebman JF (1985) Antagonism of L-5-hydroxytryptophan-induced head-twitching in rats by lisuride: a mixed 5-hydroxytryptamine agonist-antagonist? Neurosci Lett 60:207\u2013213","journal-title":"Neurosci Lett"},{"key":"1718_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","volume":"29","author":"MA Geyer","year":"2008","unstructured":"Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29:445\u2013453","journal-title":"Trends Pharmacol Sci"},{"key":"1718_CR15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0006-3223(94)90019-1","volume":"35","author":"JC Gillin","year":"1994","unstructured":"Gillin JC, Pulvirenti L, Withers N, Golshan S, Koob G (1994) The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report. Biol Psychiatry 35:843\u2013849","journal-title":"Biol Psychiatry"},{"key":"1718_CR16","first-page":"509","volume":"3","author":"RA Glennon","year":"1990","unstructured":"Glennon RA (1990) Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 3:509\u2013517","journal-title":"Neuropsychopharmacology"},{"key":"1718_CR17","first-page":"25","volume":"116","author":"RA Glennon","year":"1991","unstructured":"Glennon RA (1991) Discriminative stimulus properties of hallucinogens and related designer drugs. NIDA Res Monogr 116:25\u201344","journal-title":"NIDA Res Monogr"},{"key":"1718_CR18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/0091-3057(85)90096-6","volume":"23","author":"RA Glennon","year":"1985","unstructured":"Glennon RA, Hauck AE (1985) Mechanistic studies on DOM as a discriminative stimulus. Pharmacol Biochem Behav 23:937\u2013941","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR19","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanisms of action of hallucinogenic agents. Life Sci 35:2505\u20132511","journal-title":"Life Sci"},{"key":"1718_CR20","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1523\/JNEUROSCI.23-26-08836.2003","volume":"23","author":"J Gonz\u00e1lez-Maeso","year":"2003","unstructured":"Gonz\u00e1lez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and non-hallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836\u20138843","journal-title":"J Neurosci"},{"key":"1718_CR21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonz\u00e1lez-Maeso","year":"2007","unstructured":"Gonz\u00e1lez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 53:439\u2013452","journal-title":"Neuron"},{"key":"1718_CR22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1212\/WNL.31.4_Part_2.371","volume":"31","author":"G Gopinathan","year":"1981","unstructured":"Gopinathan G, Ter\u00e4v\u00e4inen H, Dambrosia JM, Ward CD, Sanes JN, Stuart WK, Evarts EV, Calne DB (1981) Lisuride in parkinsonism. Neurology 31:371\u2013376","journal-title":"Neurology"},{"key":"1718_CR23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/archneurpsyc.1958.02340020088016","volume":"79","author":"T Greiner","year":"1958","unstructured":"Greiner T, Burch NR, Edelberg R (1958) Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum. AMA Arch Neurol Psychiatry 79:208\u2013210","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"1718_CR24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00213-008-1247-z","volume":"201","author":"AL Halberstadt","year":"2008","unstructured":"Halberstadt AL, Buell MR, Masten VL, Risbrough VB, Geyer MA (2008) Modification of the effects of 5-methoxy-N, N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology 201:55\u201366","journal-title":"Psychopharmacology"},{"key":"1718_CR25","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","volume":"34","author":"AL Halberstadt","year":"2009","unstructured":"Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA, Powell SB (2009) 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 34:1958\u20131967","journal-title":"Neuropsychopharmacology"},{"key":"1718_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1526-4610.1977.hed1702054.x","volume":"17","author":"WM Herrmann","year":"1977","unstructured":"Herrmann WM, Horowski R, Dannehl K, Kramer U, Lurati K (1977) Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide. Headache 17:54\u201360","journal-title":"Headache"},{"key":"1718_CR27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0014-2999(82)90349-1","volume":"81","author":"AM Holohean","year":"1982","unstructured":"Holohean AM, White FJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. Eur J Pharmacol 81:595\u2013602","journal-title":"Eur J Pharmacol"},{"key":"1718_CR28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0006-8993(77)90423-1","volume":"132","author":"BL Jacobs","year":"1977","unstructured":"Jacobs BL, Trulson ME, Stern WC (1977) Behavioral effects of LSD in the cats: proposal of an animal behavioral model for studying the actions of hallucinogenic drugs. Brain Res 132:301\u2013314","journal-title":"Brain Res"},{"key":"1718_CR29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0091-3057(95)00160-X","volume":"52","author":"C Johansson","year":"1995","unstructured":"Johansson C, Jackson DM, Zhang J, Svensson L (1995) Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats. Pharmacol Biochem Behav 52:649\u2013654","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0165-6147(00)89032-X","volume":"16","author":"T Kenakin","year":"1995","unstructured":"Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232\u2013238","journal-title":"Trends Pharmacol Sci"},{"key":"1718_CR31","first-page":"105","volume":"2","author":"KK Kimura","year":"1991","unstructured":"Kimura KK, Akai TT, Nakamura KK, Yamaguchi MM, Nakagawa H, Oshino NN (1991) Dual activation by lisuride of central serotonin 5-HT1A and dopamine D2 receptor sites: drug discrimination and receptor binding studies. Behav Pharmacol 2:105\u2013112","journal-title":"Behav Pharmacol"},{"key":"1718_CR32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0893-133X(97)00164-4","volume":"18","author":"K Krebs-Thomson","year":"1998","unstructured":"Krebs-Thomson K, Paulus MP, Geyer MA (1998) Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339\u2013351","journal-title":"Neuropsychopharmacology"},{"key":"1718_CR33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0028-3908(78)90109-0","volume":"17","author":"DM Kuhn","year":"1978","unstructured":"Kuhn DM, White FJ, Appel JB (1978) The discriminative stimulus properties of LSD: mechanisms of action. Neuropharmacology 17:257\u2013263","journal-title":"Neuropharmacology"},{"key":"1718_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.102.042184","volume":"304","author":"DM Kurrasch-Orbaugh","year":"2003","unstructured":"Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE (2003) Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharrmacol Exp Ther 304:229\u2013237","journal-title":"J Pharrmacol Exp Ther"},{"key":"1718_CR35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/0-89603-122-5:299","volume-title":"Drugs as tools in neurotransmitter research. Neuromethods","author":"JE Leysen","year":"1989","unstructured":"Leysen JE (1989) Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AA, Baker GB, Butterworth R (eds) Drugs as tools in neurotransmitter research. Neuromethods, vol 12. Springer, Berlin, pp 299\u2013350"},{"key":"1718_CR36","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/WNL.31.8.961","volume":"31","author":"A Lieberman","year":"1981","unstructured":"Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, Kleinberg D (1981) Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa. Neurology 31:961\u2013965","journal-title":"Neurology"},{"key":"1718_CR37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.410130110","volume":"13","author":"AN Lieberman","year":"1983","unstructured":"Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E (1983) Bromocriptine and lisuride in Parkinson disease. Ann Neurol 13:44\u201347","journal-title":"Ann Neurol"},{"key":"1718_CR38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1210\/jcem-46-2-196","volume":"46","author":"A Liuzzi","year":"1978","unstructured":"Liuzzi A, Chiodini PG, Oppizzi G, Botalla L, Verde G, De Stefano L, Colussi G, Gr\u00e4f KJ, Horowski R (1978) Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. J Clin Endocrinol Metab 46:196\u2013202","journal-title":"J Clin Endocrinol Metab"},{"key":"1718_CR39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00212846","volume":"94","author":"RS Mansbach","year":"1988","unstructured":"Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology 94:507\u2013514","journal-title":"Psychopharmacology"},{"key":"1718_CR40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/BF00426460","volume":"73","author":"JL Marini","year":"1981","unstructured":"Marini JL, Jacobs BL, Sheard MH, Trulson ME (1981) Activity of a non-hallucinogenic ergoline derivative, lisuride, in an animal behavior model for hallucinogens. Psychopharmacology 73:328\u2013331","journal-title":"Psychopharmacology"},{"key":"1718_CR41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-002-1141-z","volume":"164","author":"D Marona-Lewicka","year":"2002","unstructured":"Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE (2002) Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology 164:93\u2013107","journal-title":"Psychopharmacology"},{"key":"1718_CR42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-008-1238-0","volume":"203","author":"D Marona-Lewicka","year":"2009","unstructured":"Marona-Lewicka D, Chemel BR, Nichols DE (2009) Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology 203:265\u2013277","journal-title":"Psychopharmacology"},{"key":"1718_CR43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0024-3205(80)90654-2","volume":"26","author":"RB McCall","year":"1980","unstructured":"McCall RB, Aghajanian GK (1980) Hallucinogens potentiate responses to serotonin and norepinephrine in the facial motor nucleus. Life Sci 26:1149\u20131156","journal-title":"Life Sci"},{"key":"1718_CR44","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","volume":"303","author":"MJ Millan","year":"2002","unstructured":"Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding properties of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791\u2013804","journal-title":"J Pharmacol Exp Ther"},{"key":"1718_CR45","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1124\/jpet.102.039875","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (2002a) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and alpha1\/alpha2-adrenoceptor. J Pharmacol Exp Ther 303:805\u2013814","journal-title":"J Pharmacol Exp Ther"},{"key":"1718_CR46","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verri\u00e8le L, Carpentier N, Millan MJ (2002b) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes. J Pharmacol Exp Ther 303:815\u2013822","journal-title":"J Pharmacol Exp Ther"},{"key":"1718_CR47","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","volume":"108","author":"DE Nichols","year":"2008","unstructured":"Nichols DE, Nichols CD (2008) Serotonin receptors. Chem Rev 108:1614\u20131641","journal-title":"Chem Rev"},{"key":"1718_CR48","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1021\/jm020153s","volume":"45","author":"DE Nichols","year":"2002","unstructured":"Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (2002) Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD). J Med Chem 45:4344\u20134349","journal-title":"J Med Chem"},{"key":"1718_CR49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0893-133X(01)00282-2","volume":"25","author":"A Ouagazzal","year":"2001","unstructured":"Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001) Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25:565\u2013575","journal-title":"Neuropsychopharmacology"},{"key":"1718_CR50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410090109","volume":"9","author":"JD Parkes","year":"1981","unstructured":"Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism. Ann Neurol 9:48\u201352","journal-title":"Ann Neurol"},{"key":"1718_CR51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(96)00454-2","volume":"312","author":"MF Piercey","year":"1996","unstructured":"Piercey MF, Hoffmann WE, Smith MW, Hyslop DK (1996) Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312:35\u201344","journal-title":"Eur J Pharmacol"},{"key":"1718_CR52","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/0024-3205(78)90057-7","volume":"22","author":"M Pieri","year":"1978","unstructured":"Pieri M, Schaffner R, Pieri L, Da Prada M, Haefely W (1978) Turning in MFB-lesioned rats and antagonism of neuroleptic-induced catalepsy after lisuride and LSD. Life Sci 22:1615\u20131622","journal-title":"Life Sci"},{"key":"1718_CR53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0091-3057(01)00720-1","volume":"72","author":"RA Rabin","year":"2002","unstructured":"Rabin RA, Regina M, Doat M, Winter JC (2002) 5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav 72:29\u201337","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1526-4610.1983.hed2303117.x","volume":"23","author":"E Raffaelli Jr","year":"1983","unstructured":"Raffaelli E Jr, Martins OJ, dos Santos P, D\u00e3gua Filho A (1983) Lisuride in cluster headache. Headache 23:117\u2013121","journal-title":"Headache"},{"key":"1718_CR55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF00441948","volume":"98","author":"B Sadzot","year":"1989","unstructured":"Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan C-R, Titeler M (1989) Hallucinogenic drug interactions at human brains 5-HT2 receptor: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98:495\u2013499","journal-title":"Psychopharmacology"},{"key":"1718_CR56","first-page":"203","volume":"146","author":"E Sanders-Bush","year":"1994","unstructured":"Sanders-Bush E (1994) Neurochemical evidence that hallucinogenic drugs are 5-HT1C receptor agonists: what next? NIDA Res Monogr 146:203\u2013213","journal-title":"NIDA Res Monogr"},{"issue":"8152","key":"1718_CR57","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(79)92523-6","volume":"2","author":"M Schachter","year":"1979","unstructured":"Schachter M, Blackstock J, Dick JP, George RJ, Marsden CD, Parkes JD (1979) Lisuride in Parkinson\u2019s disease. Lancet 2(8152):1129","journal-title":"Lancet"},{"key":"1718_CR58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0278-5846(01)00214-7","volume":"26","author":"LG Schmidt","year":"2002","unstructured":"Schmidt LG, Kuhn S, Smolka M, Schmidt K, Rommelspacher H (2002) Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog Neuropsychopharmacol Biol Psychiatry 26:209\u2013217","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1718_CR59","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(94)90643-2","volume":"264","author":"R Schreiber","year":"1994","unstructured":"Schreiber R, Brocco M, Millan MJ (1994) Blockade of the discriminative stimulus effect of DOI by MDL 100, 907 and the \u2018atypical\u2019 antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99\u2013102","journal-title":"Eur J Pharmacol"},{"key":"1718_CR60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)09485-6","volume":"273","author":"R Schreiber","year":"1995","unstructured":"Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2, 5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A\/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101\u2013112","journal-title":"J Pharmacol Exp Ther"},{"key":"1718_CR61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0028-3908(94)90074-4","volume":"33","author":"TE Sipes","year":"1994","unstructured":"Sipes TE, Geyer MA (1994) Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 33:441\u2013448","journal-title":"Neuropharmacology"},{"key":"1718_CR62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02245096","volume":"117","author":"TE Sipes","year":"1995","unstructured":"Sipes TE, Geyer MA (1995a) 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100, 135 and localization of site of action. Psychopharmacology 117:41\u201348","journal-title":"Psychopharmacology"},{"key":"1718_CR63","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","volume":"6","author":"TE Sipes","year":"1995","unstructured":"Sipes TE, Geyer MA (1995b) DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2A and not by 5-HT2C receptors. Behav Pharmacol 6:839\u2013842","journal-title":"Behav Pharmacol"},{"key":"1718_CR64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1526-4610.1978.hed1802075.x","volume":"18","author":"BW Somerville","year":"1978","unstructured":"Somerville BW, Herrmann WM (1978) Migraine prophylaxis with Lisuride hydrogen maleate\u2014a double blind study of Lisuride versus placebo. Headache 18:75\u201379","journal-title":"Headache"},{"key":"1718_CR65","first-page":"483","volume":"64","author":"WA Stoll","year":"1949","unstructured":"Stoll WA (1949) Ein neues, in sehr kleinen mengen wirksames phantastikum. Schweiz Arch neurol 64:483\u2013484","journal-title":"Schweiz Arch neurol"},{"key":"1718_CR66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","volume":"94","author":"M Titeler","year":"1988","unstructured":"Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213\u2013216","journal-title":"Psychopharmacology"},{"issue":"Pt 1B","key":"1718_CR67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/brain\/114.1.601","volume":"114","author":"J Vaamonde","year":"1991","unstructured":"Vaamonde J, Luquin MR, Obeso JA (1991) Subcutaneous lisuride infusion in Parkinson\u2019s disease. Response to chronic administration in 34 patients. Brain 114(Pt 1B):601\u2013617","journal-title":"Brain"},{"key":"1718_CR68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-100-1-78","volume":"100","author":"ML Vance","year":"1984","unstructured":"Vance ML, Evans WS, Thorner MO (1984) Drugs five years later. Bromocriptine. Ann Intern Med 100:78\u201391","journal-title":"Ann Intern Med"},{"key":"1718_CR69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF03349379","volume":"3","author":"G Verde","year":"1980","unstructured":"Verde G, Chiodini PG, Liuzzi A, Cozzi R, Favales F, Botalla L, Spelta B, Dalla Bonzana D, Rainer E, Horowski R (1980) Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. J Endocrinol Invest 3:405\u2013414","journal-title":"J Endocrinol Invest"},{"key":"1718_CR70","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0091-3057(01)00552-4","volume":"69","author":"SP Vickers","year":"2001","unstructured":"Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA (2001) Modulation of 5-HT2A receptor-mediated head-twitch behaviour in the rat by 5-HT2C receptor agonists. Pharmacol Biochem Behav 69:643\u2013652","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR71","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897\u20133902","journal-title":"NeuroReport"},{"key":"1718_CR72","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","volume":"32","author":"FX Vollenweider","year":"2007","unstructured":"Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB (2007) The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32:1876\u20131887","journal-title":"Neuropsychopharmacology"},{"key":"1718_CR73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02245940","volume":"118","author":"VJ Watts","year":"1995","unstructured":"Watts VJ, Lawler CP, Rox DR, Neve KA, Nichols DE, Mailman RB (1995) LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology 118:401\u2013409","journal-title":"Psychopharmacology"},{"key":"1718_CR74","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1126\/science.7071600","volume":"216","author":"FJ White","year":"1982","unstructured":"White FJ, Appel JB (1982) Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions. Science 216:535\u2013537","journal-title":"Science"},{"key":"1718_CR75","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0028-3908(83)90089-8","volume":"22","author":"FJ White","year":"1983","unstructured":"White FJ, Wang RY (1983) Comparison of the effects of LSD and lisuride on A10 dopamine neurons in the rat. Neuropharmacology 22:669\u2013676","journal-title":"Neuropharmacology"},{"key":"1718_CR76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)21593-2","volume":"231","author":"FJ White","year":"1984","unstructured":"White FJ, Wang RY (1984) Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies. J Pharmacol Exp Ther 231:275\u2013280","journal-title":"J Pharmacol Exp Ther"},{"key":"1718_CR77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0091-3057(81)90400-7","volume":"14","author":"FJ White","year":"1981","unstructured":"White FJ, Holohean AM, Appel JB (1981) Lack of specificity of an animal behavior model for hallucinogenic drug action. Pharmacol Biochem Behav 14:330\u2013343","journal-title":"Pharmacol Biochem Behav"},{"key":"1718_CR78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00008877-199106000-00007","volume":"2","author":"M Yamaguchi","year":"1991","unstructured":"Yamaguchi M, Kimura-Iwasaki K, Akai T, Nakada Y, Nakagawa H (1991) Terguride, a dopamine D(2) partial agonist, as a discriminative stimulus in rats. Behav Pharmacol 2:233\u2013240","journal-title":"Behav Pharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-009-1718-x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T11:38:17Z","timestamp":1739446697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-009-1718-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,25]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1007\/s00213-009-1718-x","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,25]]}}}